Ascendis Pharma A/S Target Price

Where could ASND trade next? Consensus target price: $310.

Get informed when a big investor buys or sells

+ Follow

Share Price

$244.59

Average Target Price

$311.00

27.2% upside

5 analysts in the last 4 months

High: $345 | Low: $275

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-07-23	Morgan Stanley	$275	12.4% upside
2026-07-07	RBC Capital	$280	14.5% upside
2026-05-15	Evercore ISI	$329	34.5% upside
2026-05-11	Barclays	$345	41.1% upside
2026-05-08	Wells Fargo	$326	33.3% upside
2026-03-05	Jefferies	$262	7.1% upside
2026-03-04	Stifel NicolausAlex Thompson	$332	35.7% upside
2026-03-02	Wolfe ResearchKalpit Patel	$260	6.3% upside
2026-03-02	Cantor FitzgeraldLi Watsek	$300	22.7% upside
2026-03-02	Evercore ISIJosh Schimmer	$324	32.5% upside
2026-03-02	Goldman SachsPaul Choi	$255	4.3% upside
2026-02-12	Wedbush	$273	11.6% upside
2026-02-12	Oppenheimer	$262	7.1% upside
2026-02-12	Stifel NicolausAlex Thompson	$325	32.9% upside
2026-02-12	Morgan StanleyMaxwell Skor	$256	4.7% upside
2026-01-27	BarclaysEliana Merle	$342	39.8% upside
2026-01-20	RBC Capital	$250	2.2% upside
2026-01-20	Wells FargoDerek Archila	$330	34.9% upside
2026-01-09	Wells Fargo	$322	31.6% upside
2025-12-11	Stifel NicolausAlex Thompson	$256	4.7% upside
2025-10-13	Cantor FitzgeraldLi Watsek	$254	3.8% upside
2025-08-08	RBC CapitalLuca Issi	$230	6% downside
2025-02-18	Morgan Stanley	$180	26.4% downside
2024-09-23	Bank of America SecuritiesTazeen Ahmad	$191	21.9% downside
2024-09-17	Evercore ISIGavin Clark-Gartner	$205	16.2% downside
2024-09-17	OppenheimerLeland Gershell	$190	22.3% downside
2024-09-17	CitigroupDavid Lebowitz	$207	15.4% downside
2024-09-17	Wells FargoDerek Archila	$289	18.2% upside
2024-09-16	Bank of America SecuritiesTazeen Ahmad	$175	28.5% downside
2024-09-16	Goldman SachsPaul Choi	$200	18.2% downside
2024-09-13	CitigroupDavid Lebowitz	$178	27.2% downside
2024-09-05	OppenheimerLeland Gershell	$180	26.4% downside
2024-08-13	JefferiesKelly Shi	$196	19.9% downside
2024-05-30	Stifel NicolausAlex Thompson	$200	18.2% downside
2024-05-15	Morgan StanleyVikram Purohit	$140	42.8% downside
2024-03-14	Evercore ISIJosh Schimmer	$191	21.9% downside
2023-01-03	Wells Fargo	$177	27.6% downside
2022-11-15	Morgan Stanley	$148	39.5% downside
2022-11-14	Leerink Partners	$148	39.5% downside
2022-11-14	Wedbush	$164	32.9% downside
2022-03-20	Bank of America SecuritiesTazeen Ahmad	$161	34.2% downside
2022-02-28	CitigroupDavid Lebovitz	$187	23.5% downside
2022-01-06	Cowen & Co.Yaron Werber	$136	44.4% downside
2021-07-07	Canaccord GenuityMichelle Gilson	$196	19.9% downside
2021-06-14	Cantor FitzgeraldAlethia Young	$201	17.8% downside

Ascendis Pharma A/S (ASND) FAQ

Ascendis Pharma A/S's target price stands at $310. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $310 for ASND implies 27.2% upside versus today's price ($244.59). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Ascendis Pharma A/S's target price evolved across reporting periods, while the comparison chart places ASND next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Ascendis Pharma A/S's reading of $310 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.